Dare Competitors
| DARE Stock | USD 1.68 0.09 5.08% |
Dare Bioscience vs Hoth Therapeutics Correlation
Good diversification
The correlation between Dare Bioscience and HOTH is -0.08 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Dare Bioscience and HOTH in the same portfolio, assuming nothing else is changed.
Moving against Dare Stock
| 0.56 | AHG | Akso Health Group | PairCorr |
| 0.49 | IHC | Inspiration Healthcare | PairCorr |
| 0.39 | AHC | Austco Healthcare | PairCorr |
| 0.37 | IVF | INVO Fertility Symbol Change | PairCorr |
| 0.34 | EMV | Emvision Medical Devices | PairCorr |
Dare Bioscience Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Dare Bioscience and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Dare and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Dare Bioscience does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Dare Stock performing well and Dare Bioscience Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Dare Bioscience's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| FBLG | 6.02 | (0.06) | 0.00 | 0.28 | 0.00 | 14.71 | 47.13 | |||
| CTXR | 4.47 | (1.00) | 0.00 | (0.39) | 0.00 | 10.59 | 38.23 | |||
| LPTX | 14.85 | 6.26 | 0.64 | 1.07 | 6.90 | 25.00 | 65.13 | |||
| AIMD | 4.50 | (0.74) | 0.00 | (0.16) | 0.00 | 12.30 | 38.73 | |||
| ATHA | 4.12 | 0.45 | 0.10 | 0.38 | 4.10 | 6.70 | 71.83 | |||
| ASBP | 8.33 | (2.53) | 0.00 | 1.28 | 0.00 | 19.52 | 66.08 | |||
| ADTX | 10.13 | (2.79) | 0.00 | (3.16) | 0.00 | 22.54 | 63.67 | |||
| PALI | 5.85 | (0.04) | 0.00 | 0.11 | 0.00 | 13.66 | 31.35 | |||
| ANL | 8.59 | 3.96 | 0.53 | (5.96) | 5.44 | 25.00 | 100.98 | |||
| HOTH | 2.61 | (0.85) | 0.00 | (0.42) | 0.00 | 4.81 | 14.85 |
Cross Equities Net Income Analysis
Compare Dare Bioscience and related stocks such as FibroBiologics Common, Citius Pharmaceuticals, and Leap Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FBLG | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.6 M) | (5.1 M) | (16.5 M) | (11.2 M) | (10 M) | (10.5 M) |
| CTXR | (26.3 K) | (22 K) | (31.4 K) | (1.3 M) | (2.9 M) | (8.3 M) | (10.4 M) | (12.5 M) | (15.6 M) | (17.5 M) | (23.1 M) | (33.6 M) | (32.5 M) | (39.1 M) | (37.4 M) | (33.7 M) | (32 M) |
| AIMD | (300 K) | (1.3 M) | (650.8 K) | (622.6 K) | (622.6 K) | (521.9 K) | (670 K) | (617.4 K) | (1.3 M) | (1.6 M) | (1.5 M) | (3.9 M) | (14 M) | (13.8 M) | (14.9 M) | (13.4 M) | (12.7 M) |
| ASBP | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | (25.5 K) | 3.3 M | 4.5 M | (12.5 M) | (11.3 M) | (10.7 M) |
| ADTX | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (5.7 M) | (5.8 M) | (9.1 M) | (46.4 M) | (27.6 M) | (32.4 M) | (34.4 M) | (31 M) | (32.6 M) |
| PALI | (1.7 M) | (12.5 M) | (10.1 M) | (19.8 M) | (22.6 M) | (20.9 M) | (21.1 M) | (15.7 M) | (4.9 M) | (8.4 M) | (10.3 M) | (26.6 M) | (14.3 M) | (12.3 M) | (14.4 M) | (13 M) | (13.6 M) |
| ANL | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (17.8 M) | (63.4 M) | (56.7 M) | (58.8 M) | (104.9 M) | (51.9 M) | (46.7 M) | (49 M) |
| HOTH | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2.5 M) | (7.7 M) | (7.2 M) | (14.3 M) | (11.4 M) | (7.8 M) | (8.2 M) | (7.4 M) | (7.7 M) |
Dare Bioscience and related stocks such as FibroBiologics Common, Citius Pharmaceuticals, and Leap Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Dare Bioscience financial statement analysis. It represents the amount of money remaining after all of Dare Bioscience operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Dare Bioscience Competitive Analysis
The better you understand Dare Bioscience competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Dare Bioscience's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Dare Bioscience's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Dare Bioscience Competition Performance Charts
Five steps to successful analysis of Dare Bioscience Competition
Dare Bioscience's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Dare Bioscience in relation to its competition. Dare Bioscience's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Dare Bioscience in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Dare Bioscience's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Dare Bioscience, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Dare Bioscience position
In addition to having Dare Bioscience in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Diversified Assets Thematic Idea Now
Diversified Assets
Pablicly traded close-end funds and other entities backed by different types of diversified investments. The Diversified Assets theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Diversified Assets Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Dare Bioscience Correlation with its peers. For information on how to trade Dare Stock refer to our How to Trade Dare Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Will Health Care Equipment & Supplies sector continue expanding? Could Dare diversify its offerings? Factors like these will boost the valuation of Dare Bioscience. Projected growth potential of Dare fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Dare Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.83) | Revenue Per Share | Quarterly Revenue Growth (0.95) | Return On Assets | Return On Equity |
Understanding Dare Bioscience requires distinguishing between market price and book value, where the latter reflects Dare's accounting equity. The concept of intrinsic value - what Dare Bioscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Dare Bioscience's price substantially above or below its fundamental value.
It's important to distinguish between Dare Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dare Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Dare Bioscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.